The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Diane M. Harper; Pekka Nieminen; Gilbert Donders; Mark H. Einstein; Francisco Garcia; Warner K. Huh; Mark H. Stoler; Katerina Glavini; Gemma Attley; Jean Marc Limacher; Berangere Bastien; Elizabeth Calleja

doi:10.1097/OGX.0000000000000710

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Diane M. Harper
, Pekka Nieminen
, Gilbert Donders
, Mark H. Einstein
, Francisco Garcia
, Warner K. Huh
, Mark H. Stoler
, Katerina Glavini
, Gemma Attley
, Jean Marc Limacher
, Berangere Bastien
, Elizabeth Calleja

Health Promotion Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

Original language	English (US)
Pages (from-to)	529-530
Number of pages	2
Journal	Obstetrical and Gynecological Survey
Volume	74
Issue number	9
DOIs	https://doi.org/10.1097/OGX.0000000000000710
State	Published - Sep 1 2019

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/OGX.0000000000000710

Cite this

Harper, D. M., Nieminen, P., Donders, G., Einstein, M. H., Garcia, F., Huh, W. K., Stoler, M. H., Glavini, K., Attley, G., Limacher, J. M., Bastien, B., & Calleja, E. (2019). The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up. Obstetrical and Gynecological Survey, 74(9), 529-530. https://doi.org/10.1097/OGX.0000000000000710

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up. / Harper, Diane M.; Nieminen, Pekka; Donders, Gilbert et al.
In: Obstetrical and Gynecological Survey, Vol. 74, No. 9, 01.09.2019, p. 529-530.

Research output: Contribution to journal › Comment/debate › peer-review

Harper, DM, Nieminen, P, Donders, G, Einstein, MH, Garcia, F, Huh, WK, Stoler, MH, Glavini, K, Attley, G, Limacher, JM, Bastien, B & Calleja, E 2019, 'The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up', Obstetrical and Gynecological Survey, vol. 74, no. 9, pp. 529-530. https://doi.org/10.1097/OGX.0000000000000710

@article{ae4fbc402e1a4a0fa5f8dca3878f81af,

title = "The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up",

abstract = "On a global scale, cervical cancer comprises approximately 80\% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.",

author = "Harper, \{Diane M.\} and Pekka Nieminen and Gilbert Donders and Einstein, \{Mark H.\} and Francisco Garcia and Huh, \{Warner K.\} and Stoler, \{Mark H.\} and Katerina Glavini and Gemma Attley and Limacher, \{Jean Marc\} and Berangere Bastien and Elizabeth Calleja",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/OGX.0000000000000710",

language = "English (US)",

volume = "74",

pages = "529--530",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3

T2 - Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

AU - Harper, Diane M.

AU - Nieminen, Pekka

AU - Donders, Gilbert

AU - Einstein, Mark H.

AU - Garcia, Francisco

AU - Huh, Warner K.

AU - Stoler, Mark H.

AU - Glavini, Katerina

AU - Attley, Gemma

AU - Limacher, Jean Marc

AU - Bastien, Berangere

AU - Calleja, Elizabeth

PY - 2019/9/1

Y1 - 2019/9/1

N2 - On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

AB - On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

UR - https://www.scopus.com/pages/publications/85077575722

UR - https://www.scopus.com/pages/publications/85077575722#tab=citedBy

U2 - 10.1097/OGX.0000000000000710

DO - 10.1097/OGX.0000000000000710

M3 - Comment/debate

AN - SCOPUS:85077575722

SN - 0029-7828

VL - 74

SP - 529

EP - 530

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 9

ER -

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this